Literature DB >> 26032359

A Bacterial Metabolite, Compound K, Induces Programmed Necrosis in MCF-7 Cells via GSK3β.

Chae Won Kwak1, Young Min Son1, Min Jeong Gu1,2, Girak Kim1, In Kyu Lee1, Yoon Chul Kye1, Han Wool Kim1, Ki-Duk Song1, Hyuk Chu3, Byung-Chul Park4, Hak-Kyo Lee5, Deok-Chun Yang6, Jonathan Sprent7, Cheol-Heui Yun1,2,4.   

Abstract

Ginsenosides, the major active component of ginseng, are traditionally used to treat various diseases, including cancer, inflammation, and obesity. Among these, compound K (CK), an intestinal bacterial metabolite of the ginsenosides Rb1, Rb2, and Rc from Bacteroides JY-6, is reported to inhibit cancer cell growth by inducing cell-cycle arrest or cell death, including apoptosis and necrosis. However, the precise effect of CK on breast cancer cells remains unclear. MCF-7 cells were treated with CK (0-70 micrometer) for 24 or 48 h. Cell proliferation and death were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry assays, respectively. Changes in downstream signaling molecules involved in cell death, including glycogen synthase kinase 3β (GSK3β), GSK3β, β-catenin, and cyclin D1, were analyzed by western blot assay. To block GSK3β signaling, MCF-7 cells were pretreated with GSK3β inhibitors 1 h prior to CK treatment. Cell death and the expression of β-catenin and cyclin D1 were then examined. CK dose- and time-dependently inhibited MCF-7 cell proliferation. Interestingly, CK induced programmed necrosis, but not apoptosis, via the GSK3β signaling pathway in MCF-7 cells. CK inhibited GSK3β phosphorylation, thereby suppressing the expression of β-catenin and cyclin D1. Our results suggest that CK induces programmed necrosis in MCF-7 breast cancer cells via the GSK3β signaling pathway.

Entities:  

Keywords:  GSK3β; MCF-7; breast cancer cells; compound K; ginsenoside; programmed necrosis

Mesh:

Substances:

Year:  2015        PMID: 26032359     DOI: 10.4014/jmb.1505.05057

Source DB:  PubMed          Journal:  J Microbiol Biotechnol        ISSN: 1017-7825            Impact factor:   2.351


  7 in total

Review 1.  Functional Mechanism of Ginsenoside Compound K on Tumor Growth and Metastasis.

Authors:  Jinlong Liu; Yuchen Wang; Zhun Yu; Guangfu Lv; Xiaowei Huang; He Lin; Chao Ma; Zhe Lin; Peng Qu
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

Review 2.  Ginsenoside Compound K: Insights into Recent Studies on Pharmacokinetics and Health-Promoting Activities.

Authors:  Anshul Sharma; Hae-Jeung Lee
Journal:  Biomolecules       Date:  2020-07-10

3.  Compound K Induces Endoplasmic Reticulum Stress and Apoptosis in Human Liver Cancer Cells by Regulating STAT3.

Authors:  Xuan Zhang; Silin Zhang; Qitong Sun; Wenjun Jiao; Yan Yan; Xuewu Zhang
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411

Review 4.  Application of Nanoparticles in the Treatment of Lung Cancer With Emphasis on Receptors.

Authors:  Jingyue Wang; Tong Zhou; Ying Liu; Shuangmin Chen; Zhenxiang Yu
Journal:  Front Pharmacol       Date:  2022-01-10       Impact factor: 5.810

Review 5.  A narrative review of the pharmacology of ginsenoside compound K.

Authors:  Tao Liu; Lu Zhu; Li Wang
Journal:  Ann Transl Med       Date:  2022-02

Review 6.  Anticancer properties and pharmaceutical applications of ginsenoside compound K: A review.

Authors:  Li Zhou; Zhong-Kun Li; Cong-Yuan Li; Yue-Qin Liang; Fan Yang
Journal:  Chem Biol Drug Des       Date:  2021-11-25       Impact factor: 2.873

Review 7.  Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy.

Authors:  Mao-Bin Meng; Huan-Huan Wang; Yao-Li Cui; Zhi-Qiang Wu; Yang-Yang Shi; Nicholas G Zaorsky; Lei Deng; Zhi-Yong Yuan; You Lu; Ping Wang
Journal:  Oncotarget       Date:  2016-08-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.